Aurora Cannabis Takeover Bid: Curaleaf, Organigram and the Fight for Control
This hub tracks the contest for control of Aurora Cannabis, the Edmonton-based Canadian licensed producer. Curaleaf has a bid on the table that is set to expire Dec. 4, and as of October 2026 Organigram has entered the fight. British American Tobacco's stake in Organigram could put it at the center of the contest. The page explains who the parties are, how takeover bids work in Canada, what shareholders and regulators must decide, and what could happen before the deadline. It is updated as filings, board responses, and competing offers are reported.
Executive summary
Curaleaf's offer for Aurora Cannabis expires Dec. 4, 2026, and Organigram's entry on Oct. 13 turned a one-bidder takeover into a contested situation. Reporting from MJBizDaily said British American Tobacco's (BAT) stake in Organigram could put the tobacco giant in the middle of the fight. This page is the running reference for that contest.
The deal pairs two very different companies. Curaleaf is one of the largest U.S. multi-state operators (MSO). Aurora Cannabis is an Alberta-based Canadian licensed producer with a large medical business in Germany and other export markets. Organigram is a New Brunswick-based licensed producer whose strategic shareholder is BAT.
Four facts frame the story as of Oct. 13, 2026:
- The Curaleaf bid has a hard expiry of Dec. 4, 2026, about 52 days after Organigram's entry.
- Organigram has entered the contest, and BAT's shareholding gives it potential influence over how Organigram can act.
- Canadian take-over bid rules, the Canada Business Corporations Act, Health Canada licensing, and U.S. federal cannabis law all shape what any bidder can do.
- Aurora's board and shareholders now have competing options, which usually moves price and terms.
Scope note: The triggering MJBizDaily item gives the Dec. 4 expiry and the BAT-Organigram angle. It does not give price, consideration mix, or conditions. This foundation edition does not invent those terms. For the controlling numbers, read the offer documents and Aurora's directors' circular on SEDAR+ (linked under Further reading). We will append dated updates as terms, board responses, and regulatory filings emerge.
Why this matters
A Curaleaf-Aurora combination, or an Organigram-led rival outcome, would redraw the Canadian licensed-producer map and test whether U.S. MSOs can buy their way into Canada and Europe's medical markets.
Five stakeholder groups have money or strategy at stake:
- Aurora shareholders. They choose between a live bid, a possible competing proposal, and the standalone plan. Competitive tension is the main source of price leverage in a Canadian take-over contest.
- Curaleaf shareholders. They are asked to fund or support an acquisition of a company with a different regulatory profile. Aurora has no U.S. plant-touching operations, and Curaleaf is a U.S. MSO that is federally illegal under the Controlled Substances Act.
- Organigram and BAT. Organigram has consolidated aggressively. BAT, a global nicotine and tobacco group, has been a strategic investor and decides how much it will support or constrain a deal.
- Medical patients and export customers. Aurora's international medical franchise, including Germany, is among the assets that make the company strategic. Continuity of supply matters for patients and for pharmacy partners.
- Canadian regulators and provincial wholesalers. Health Canada licensing, competition review, and provincial boards will all touch a change of control.
The deal matters beyond its dollar value because Canada was the first G7 country to legalize adult-use cannabis, on Oct. 17, 2018. Its licensed-producer sector has been consolidating ever since. Tilray, Canopy Growth, and SNDL have all done deals. A fight for Aurora, with a U.S. MSO on one side and a BAT-backed Canadian producer on the other, would be the sector's clearest test of strategic buyers against each other.
Background and history
Aurora's path from 2018 Canadian champion to 2026 takeover target runs through a boom, a write-down cycle, and a pivot to medical cannabis, and every phase shapes why bidders want it now.
2013-2017: Founding and the hostile-bid precedent
Aurora was founded in 2013 and built its early reputation on large-scale indoor cultivation in Alberta. Health Canada licensed its first facility under the medical cannabis regime in 2014. The company grew by acquisition and by building capacity, and in late 2017 it launched a hostile take-over of CanniMed Therapeutics, a Saskatchewan producer with a rival agreed deal. Aurora won in early 2018 after a bruising contest. The precedent matters because Aurora knows both sides of a contested Canadian bid.
2018: Legalization and the MedReleaf deal
Canada's Cannabis Act took effect on Oct. 17, 2018. In the same year Aurora agreed to buy MedReleaf, an Ontario producer, in a deal valued at about C$3.2 billion. That year also saw Constellation Brands' roughly C$5 billion investment in Canopy Growth, which set the sector's peak valuation logic: scale first, profits later.
2019-2021: Over-capacity and impairments
Licensed producers built far more cultivation capacity than the early legal market could absorb. Provincial retail rollouts were slower than planned, and illicit-market competition kept prices down. Aurora recorded large impairments, cut staff, and closed or consolidated facilities. It also carried out share consolidations in 2020 and again in 2023 to manage its listing and share count. Meanwhile BAT made its strategic investment in Organigram in 2019, which began the tobacco-to-cannabis pairing now relevant in this fight.
2021-2023: Consolidation wave
The sector's response to weak margins was to merge. Tilray completed its combination with Aphria in 2021 and later bought Hexo. SNDL expanded through acquisitions. Aurora, under
Frequently asked questions
What is the Aurora Cannabis takeover bid?
It is a contested effort to acquire Aurora Cannabis, a Canadian licensed cannabis producer based in Edmonton, Alberta. MJBizDaily reports that Curaleaf has a bid for Aurora that expires Dec. 4, 2026, and that Organigram has now entered the fight. Deal terms should be confirmed in the formal offer documents filed on SEDAR+.
Who is bidding for Aurora Cannabis?
Curaleaf, a large multistate cannabis operator, has the bid reported to expire Dec. 4. Organigram, a Canadian licensed producer, has entered the contest, according to MJBizDaily's Oct. 13, 2026 report. The exact form of Organigram's involvement should be checked against its public filings and announcements.
Why does British American Tobacco matter in this fight?
British American Tobacco holds a stake in Organigram, per MJBizDaily. That stake could make BAT a major influence on any Organigram move for Aurora, whether through financing, voting, or strategy. The size of BAT's holding and any governance rights are disclosed in Organigram's public filings.
When does Curaleaf's bid for Aurora expire?
MJBizDaily reports that Curaleaf's bid expires Dec. 4. Under Canadian takeover rules, an offer can be extended, varied, or allowed to lapse, and a competing bid can change the timeline. Check the latest offer documents and press releases for the current expiry.
What can Aurora's board do in response to a takeover bid?
In Canada, a target board typically reviews the offer with financial and legal advisers and issues a recommendation to shareholders. It can recommend acceptance or rejection, seek alternative bids, or negotiate improved terms. Its directors owe duties to the corporation. The board's formal response appears in a directors' circular filed publicly.
How do shareholders decide on a takeover offer like this?
In a formal takeover bid, shareholders decide by tendering or not tendering their shares before the deadline. The offer usually carries a minimum tender condition. Under Canadian securities rules, bids generally need to stay open for a minimum period, and shareholders can compare competing offers before committing.
Could a competing bid change the outcome?
Yes. A rival offer can lead to higher prices, revised terms, extended deadlines, or a board-run auction. Organigram's entrance, and BAT's stake in Organigram, are the developments that could turn a single bid into a contested one. Any rival offer would need to be formally launched and disclosed.
What approvals could a deal for Aurora require?
Depending on structure, a deal could need shareholder acceptance, Canadian competition review, stock exchange approvals, and Health Canada licensing continuity. A bid involving a US-based acquirer may also raise cross-border listing and regulatory questions. Specific requirements are listed in the offer documents.
Where can I find the official documents on the bids?
Official documents appear on SEDAR+, the Canadian securities filing system, and in company press releases. Look for the takeover bid circular, any directors' circular from Aurora, and material change reports. Aurora and Organigram investor pages also post announcements, and trade outlets such as MJBizDaily report the developments.
What does this fight mean for the Canadian cannabis industry?
It could signal further consolidation among Canadian licensed producers, many of which have faced price pressure and slow growth. The involvement of a US multistate operator and a tobacco-backed Canadian producer underscores how international capital is shaping the sector. The long-term effects depend on how the contest resolves.
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.